SLC
TMO icon

Second Line Capital’s Thermo Fisher Scientific TMO Stock Holding History

Second Line Capital’s Portfolio TMO Stock Details TMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$244K Buy
509
+116
+30% +$63K 0.05% 154
2025
Q4 		$228K Buy
+393
New +$222K 0.05% 144

Other funds holding TMO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Second Line Capital's TMO Position: Q1 2026 in Review

Second Line Capital increased its Thermo Fisher Scientific (TMO) stake by 30% in Q1 2026, buying an estimated $63K and bringing the position to 509 shares worth $244K. The position accounts for 0.05% of the portfolio, ranked #154.

Second Line Capital first reported a position in TMO in Q4 2025 and has held it in 2 quarters since. 2,587 funds tracked by Wall St. Rank hold TMO as of Q1 2026.

  • Second Line Capital held 509 shares of Thermo Fisher Scientific worth $244K as of Q1 2026.
  • Second Line Capital bought 116 Thermo Fisher Scientific shares in Q1 2026, an estimated $63K.
  • Thermo Fisher Scientific made up 0.05% of Second Line Capital's portfolio in Q1 2026, its #154 holding.
  • Second Line Capital first reported a position in Thermo Fisher Scientific in Q4 2025 and has held it in 2 quarters since.
  • 2,587 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q1 2026.

Based on Second Line Capital's 13F filing for Q1 2026, filed 15 May 2026.